PE20211444A1 - Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5 - Google Patents
Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5Info
- Publication number
- PE20211444A1 PE20211444A1 PE2020000761A PE2020000761A PE20211444A1 PE 20211444 A1 PE20211444 A1 PE 20211444A1 PE 2020000761 A PE2020000761 A PE 2020000761A PE 2020000761 A PE2020000761 A PE 2020000761A PE 20211444 A1 PE20211444 A1 PE 20211444A1
- Authority
- PE
- Peru
- Prior art keywords
- substituted
- unsubstituted alkyl
- halogen
- independently selected
- bicycle
- Prior art date
Links
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title abstract 3
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010915 Glioblastoma multiforme Diseases 0.000 abstract 1
- XDALKOHBSHKPME-QRVBRYPASA-N NC1=NC=NC2=C1C=CN2[C@@H]1C=C(CCC2=CC=C3C=C(Br)C(N)=NC3=C2)[C@@H](O)[C@H]1O Chemical compound NC1=NC=NC2=C1C=CN2[C@@H]1C=C(CCC2=CC=C3C=C(Br)C(N)=NC3=C2)[C@@H](O)[C@H]1O XDALKOHBSHKPME-QRVBRYPASA-N 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000005017 glioblastoma Diseases 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 201000002528 pancreatic cancer Diseases 0.000 abstract 1
- 208000008443 pancreatic carcinoma Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Referido a un compuesto que tiene la formula general I, un estereoisomero del mismo o una sal farmaceuticamente aceptable del mismo; en donde, L1 se selecciona entre -CRaRb-, -NRa-, S y O; Z se selecciona entre CH y N; Ra y Rb se seleccionan independientemente en cada aparicion entre H, alquilo sustituido o sin sustituir, entre otros; R se selecciona entre -NR4R5, H, halogeno, entre otros; R1 y R2, junto con los atomos de carbono a los que estan unidos, forman un enlace para formar un -C=C-; R2 y R2a, que pueden ser iguales o diferentes y se seleccionan independientemente entre H y alquilo sustituido o sin sustituir; R3 se selecciona independientemente en cada aparicion entre halogeno, ciano, nitro, alquilo sustituido o sin sustituir, R10 se selecciona entre hidrogeno, halogeno y alquilo sustituido o sin sustituir, entre otros; "n" es un numero entero que varia de 0 a 4. Un compuesto seleccionado es (1S,2R,5R)-3-(2-(2-Amino-3-bromoquinolin-7-il)etil)-5-(4-amino-7H-pirrolo[2,3-d]pirimidin-7-il)ciclopent-3-eno-1,2-diol. Estos componentes biciclicos sustituidos son inhibidores de PRMT5. Tambien se refiere a productos intermedios, metodos de su sintesis, y a composiciones farmaceuticas y su uso en el tratamiento de enfermedades, trastornos o afecciones asociados con la sobreexpresion de la enzima PRMT5, tales como glioblastoma multiforme, cancer de prostata, cancer de pancreas.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201721044886 | 2017-12-13 | ||
| IN201821024634 | 2018-07-02 | ||
| IN201821040029 | 2018-10-23 | ||
| PCT/IB2018/060015 WO2019116302A1 (en) | 2017-12-13 | 2018-12-13 | Substituted bicyclic heterocyclic compounds as prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211444A1 true PE20211444A1 (es) | 2021-08-05 |
Family
ID=65036860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2020000761A PE20211444A1 (es) | 2017-12-13 | 2018-12-13 | Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US11459330B2 (es) |
| EP (1) | EP3724190B1 (es) |
| JP (1) | JP7282778B2 (es) |
| KR (1) | KR102708147B1 (es) |
| CN (1) | CN111712498B (es) |
| AU (1) | AU2018385664B2 (es) |
| BR (1) | BR112020011746A2 (es) |
| CA (1) | CA3085259A1 (es) |
| CL (1) | CL2020001576A1 (es) |
| CR (1) | CR20200263A (es) |
| CU (1) | CU24621B1 (es) |
| DK (1) | DK3724190T3 (es) |
| ES (1) | ES2927860T3 (es) |
| GE (1) | GEP20227359B (es) |
| HR (1) | HRP20221207T1 (es) |
| HU (1) | HUE059945T2 (es) |
| IL (1) | IL274936B2 (es) |
| LT (1) | LT3724190T (es) |
| MX (1) | MX2020006181A (es) |
| NZ (1) | NZ765656A (es) |
| PE (1) | PE20211444A1 (es) |
| PH (1) | PH12020550881A1 (es) |
| PL (1) | PL3724190T3 (es) |
| PT (1) | PT3724190T (es) |
| RS (1) | RS63623B1 (es) |
| SG (1) | SG11202004934QA (es) |
| SM (1) | SMT202200396T1 (es) |
| UA (1) | UA126349C2 (es) |
| WO (1) | WO2019116302A1 (es) |
| ZA (1) | ZA202003528B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| JOP20210060A1 (ar) | 2018-10-05 | 2023-01-30 | Vertex Pharma | معدلات لمضاد تريبسين ألفا-1 |
| BR112021019465A8 (pt) | 2019-04-02 | 2022-06-07 | Aligos Therapeutics Inc | Compostos que têm como alvo prmt5 |
| UY38696A (es) | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
| KR20220016194A (ko) * | 2019-05-30 | 2022-02-08 | 앤젝스 파마수티컬, 인크. | Prmt5 억제제로서의 헤테로시클릭 화합물 |
| ES2967457T3 (es) * | 2019-06-10 | 2024-04-30 | Lupin Ltd | Inhibidores de PRMT5 |
| PE20221154A1 (es) | 2019-10-22 | 2022-07-18 | Lupin Ltd | Combinacion farmaceutica de inhibidores de prmt5 |
| CN115279756A (zh) * | 2019-10-25 | 2022-11-01 | 埃克森特治疗公司 | Mettl3调节剂 |
| MX2022006735A (es) * | 2019-12-03 | 2022-07-21 | Lupin Ltd | Análogos de nucleósidos sustituidos como inhibidores de la prmt5. |
| WO2021202480A1 (en) * | 2020-04-01 | 2021-10-07 | Aligos Therapeutics, Inc. | Compounds targeting prmt5 |
| WO2021203028A1 (en) * | 2020-04-03 | 2021-10-07 | Vertex Pharmaceuticals Incorporated | 7- or 8-hydroxy-isoquinoline and 7- or 8-hydroxy-quinoline derivatives as alpha-1 -antitrypsin modulators for treating alpha-1 -antitrypsin deficiency (aatd) |
| EP4188920A1 (en) | 2020-07-31 | 2023-06-07 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyrydine-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
| CR20230402A (es) | 2021-01-19 | 2023-11-21 | Lupin Ltd | Combinaciones farmacéuticas de inhibidores de sos1 para tratar o prevenir cancer |
| CN113234079B (zh) * | 2021-04-30 | 2022-02-01 | 上海湃隆生物科技有限公司 | 用作prmt5抑制剂的核苷类似物 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003251431A1 (en) | 2002-07-22 | 2004-02-09 | Cambridge University Technical Services Ltd. | Synthesis of discodermolide |
| WO2005016878A2 (en) | 2003-08-13 | 2005-02-24 | Isis Pharmaceuticals, Inc. | METHODS FOR THE PREPARATION OF 5-FLUORO-PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
| EP2049490A1 (en) | 2006-06-09 | 2009-04-22 | Astra Zeneca AB | N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors |
| WO2008107478A1 (en) | 2007-03-08 | 2008-09-12 | Janssen Pharmaceutica Nv | Quinolinone derivatives as parp and tank inhibitors |
| FR2926556B1 (fr) | 2008-01-22 | 2010-02-19 | Sanofi Aventis | Derives de carboxamides n-azabicycliques, leur preparation et leur application en therapeutique |
| US20110237606A1 (en) * | 2008-09-26 | 2011-09-29 | Agency Of Science, Technology And Research | 3-Deazaneplanocin Derivatives |
| GB0922332D0 (en) | 2009-12-22 | 2010-02-03 | Isis Innovation | Method of treatment and screening method |
| WO2011079236A1 (en) | 2009-12-22 | 2011-06-30 | The Ohio State University Research Foundation | Compositions and methods for cancer detection and treatment |
| SG186877A1 (en) | 2010-06-30 | 2013-02-28 | Fujifilm Corp | Novel nicotinamide derivatives or salts thereof |
| WO2012037108A1 (en) | 2010-09-13 | 2012-03-22 | Glaxosmithkline Llc | Aminoquinoline derivatives as antiviral agents |
| WO2012123298A1 (en) | 2011-03-11 | 2012-09-20 | F. Hoffmann-La Roche Ag | Antiviral compounds |
| ES2608053T3 (es) | 2011-08-19 | 2017-04-05 | Glaxosmithkline Intellectual Property (No. 2) Limited | Inhibidores de ácido graso sintasa |
| AU2013250726B2 (en) * | 2012-04-20 | 2017-01-05 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof |
| ES2624223T3 (es) | 2012-06-08 | 2017-07-13 | Gilead Sciences, Inc. | Inhibidores macrocíclicos de los virus flaviviridae |
| WO2014008223A2 (en) | 2012-07-03 | 2014-01-09 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
| CA2894157A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP2935240A1 (en) * | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| CA2894228C (en) | 2012-12-21 | 2021-08-17 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| JP2016505002A (ja) | 2012-12-21 | 2016-02-18 | エピザイム，インコーポレイティド | ジヒドロイソキノリンまたはテトラヒドロイソキノリンを含有するｐｒｍｔ５阻害剤およびその使用 |
| EP2935241A1 (en) | 2012-12-21 | 2015-10-28 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP2943485B1 (en) | 2013-01-14 | 2017-09-20 | Incyte Holdings Corporation | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
| GB201302927D0 (en) | 2013-02-20 | 2013-04-03 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| WO2014145214A2 (en) | 2013-03-15 | 2014-09-18 | Ohio State Innovation Foundation | Inhibitors of prmt5 and methods of their use |
| JP6559123B2 (ja) | 2013-10-10 | 2019-08-14 | アラクセス ファーマ エルエルシー | Ｋｒａｓｇ１２ｃの阻害剤 |
| BR112016024149A2 (pt) | 2014-05-22 | 2017-08-15 | Hoffmann La Roche | derivados de indolin-2-ona e 1,3-di-hidro-pirrol[3,2-c]piridin-2-ona |
| JP6559719B2 (ja) | 2014-06-25 | 2019-08-14 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | （ｓ）−６−（（１−アセチルピペリジン−４−イル）アミノ）−ｎ−（３−（３、４−ジヒドロイソキノリン−２（１ｈ）−イル）−２−ヒドロキシプロピル）ピリミジン−４−カルボキサミドの結晶塩 |
| US20170198006A1 (en) | 2014-06-25 | 2017-07-13 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| EP3160466A4 (en) | 2014-06-25 | 2017-12-27 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| AU2015301196A1 (en) | 2014-08-04 | 2017-01-12 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| WO2016034673A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Tetrahydroisoquinoline derived prmt5-inhibitors |
| WO2016034671A1 (en) | 2014-09-03 | 2016-03-10 | Ctxt Pty Ltd | Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived prmt5-inhibitors |
| GB201415573D0 (en) | 2014-09-03 | 2014-10-15 | Cancer Therapeutics Crc Pty Ltd | Compounds |
| WO2016038550A1 (en) | 2014-09-11 | 2016-03-17 | Novartis Ag | Inhibition of prmt5 to treat mtap-deficiency-related diseases |
| UA118315C2 (uk) | 2015-02-24 | 2018-12-26 | Пфайзер Інк. | Заміщені нуклеозидні похідні, прийнятні як протиракові агенти |
| EP3268044A2 (en) | 2015-03-11 | 2018-01-17 | The Broad Institute Inc. | Prmt5 inhibitors for the treatment of cancer with reduced mtap activty |
| AR104326A1 (es) | 2015-05-04 | 2017-07-12 | Lilly Co Eli | Compuestos nucleósidos 5-sustituidos |
| TWI791251B (zh) | 2015-08-26 | 2023-02-01 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| JP7015059B2 (ja) | 2015-11-16 | 2022-02-15 | アラクセス ファーマ エルエルシー | 置換複素環式基を含む２－置換キナゾリン化合物およびその使用方法 |
| WO2018065365A1 (en) * | 2016-10-03 | 2018-04-12 | Janssen Pharmaceutica Nv | Novel monocyclic and bicyclic ring system substituted carbanucleoside analogues for use as prmt5 inhibitors |
-
2018
- 2018-12-13 PE PE2020000761A patent/PE20211444A1/es unknown
- 2018-12-13 WO PCT/IB2018/060015 patent/WO2019116302A1/en active IP Right Grant
- 2018-12-13 CU CU2020000051A patent/CU24621B1/es unknown
- 2018-12-13 BR BR112020011746-3A patent/BR112020011746A2/pt unknown
- 2018-12-13 US US16/772,959 patent/US11459330B2/en active Active
- 2018-12-13 CA CA3085259A patent/CA3085259A1/en active Pending
- 2018-12-13 LT LTEPPCT/IB2018/060015T patent/LT3724190T/lt unknown
- 2018-12-13 NZ NZ765656A patent/NZ765656A/en unknown
- 2018-12-13 HU HUE18836520A patent/HUE059945T2/hu unknown
- 2018-12-13 GE GEAP201815385A patent/GEP20227359B/en unknown
- 2018-12-13 SG SG11202004934QA patent/SG11202004934QA/en unknown
- 2018-12-13 CN CN201880089329.6A patent/CN111712498B/zh active Active
- 2018-12-13 CR CR20200263A patent/CR20200263A/es unknown
- 2018-12-13 RS RS20220931A patent/RS63623B1/sr unknown
- 2018-12-13 KR KR1020207019844A patent/KR102708147B1/ko active Active
- 2018-12-13 IL IL274936A patent/IL274936B2/en unknown
- 2018-12-13 MX MX2020006181A patent/MX2020006181A/es unknown
- 2018-12-13 HR HRP20221207TT patent/HRP20221207T1/hr unknown
- 2018-12-13 SM SM20220396T patent/SMT202200396T1/it unknown
- 2018-12-13 AU AU2018385664A patent/AU2018385664B2/en active Active
- 2018-12-13 DK DK18836520.9T patent/DK3724190T3/da active
- 2018-12-13 PT PT188365209T patent/PT3724190T/pt unknown
- 2018-12-13 UA UAA202004140A patent/UA126349C2/uk unknown
- 2018-12-13 JP JP2020532614A patent/JP7282778B2/ja active Active
- 2018-12-13 PL PL18836520.9T patent/PL3724190T3/pl unknown
- 2018-12-13 ES ES18836520T patent/ES2927860T3/es active Active
- 2018-12-13 EP EP18836520.9A patent/EP3724190B1/en active Active
-
2020
- 2020-06-06 PH PH12020550881A patent/PH12020550881A1/en unknown
- 2020-06-11 CL CL2020001576A patent/CL2020001576A1/es unknown
- 2020-06-12 ZA ZA2020/03528A patent/ZA202003528B/en unknown
-
2022
- 2022-05-06 US US17/738,370 patent/US11952380B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211444A1 (es) | Componentes heterociclicos biciclicos sustituidos como inhibidores de prmt5 | |
| PE20230245A1 (es) | Inhibidores de prmt5 | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR113818A2 (es) | Pirazolo-quinazolinas como inhibidores de proteína quinasa | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| DOP2011000057A (es) | Compuestos de pirrolo-pirimidina como inhibidores de cdk | |
| AR077292A1 (es) | Derivados de piperazin - quinolin sulfonamidas y composiciones farmaceuticas | |
| AR069607A1 (es) | Inhibidores de la estearoil-coa desaturasa | |
| AR094346A1 (es) | Derivados de azaindol como inhibidores de las proteína quinasas | |
| AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
| CO5700752A2 (es) | Derivados de piperazina y piperazin-2-ona especificos al receptor de melano cortina | |
| AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
| PE20240930A1 (es) | Analogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton | |
| HN2009000968A (es) | Compuestos de pirazol y triazol sustituidos como inhibidores de ksp | |
| AR065583A1 (es) | Compuestos macrociclicos y composicion farmaceutica | |
| PE20211054A1 (es) | Compuestos de indolinona para uso como inhibidores de map4k1 | |
| PE20191032A1 (es) | Pirido[3,4-b]indoles sustituidos para tratamiento de los trastornos de los cartilagos | |
| AR073511A1 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
| MY197742A (en) | Morphinan derivative | |
| AR100776A1 (es) | Compuestos herbicidas | |
| MX2018013325A (es) | Derivados de adenina como inhibidores de proteína quinasa. | |
| PE20210404A1 (es) | Derivados de pirrolo [1,2-b] piridazina | |
| ZA202006439B (en) | Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators | |
| AR079092A1 (es) | Flavonas sustituidas por pirrolidina como radio sensibilizadores |